Free Newsletter
Fewer Prevnar jabs just as effective
A new study demonstrates that three doses of Wyeth's pneumococcal vaccine Prevnar works as well as the four-dose regimen currently in use. And a reduction in jabs could save payers a significant amount of money. "In my opinion you could safely go to two-plus-one," Elisabeth Sanders, one of the study's co-authors, told Dow Jones. "Why not save the one injection if it's not required?" Report
More stories about Prevnar
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: